An update on evidence for mineralocorticoid receptor antagonist in the treatment of central serous retinopathy

VernacularTitle:盐皮质激素受体拮抗剂治疗慢性中心性浆液性脉络膜视网膜病变的研究进展
Author: Lingli ZHANG ¹ ; Hua LI ; Yufei WU ; Shengfang SONG ; Shichun LIU
Author Information

1. 重庆医科大学附属永川医院眼科 402160
Keywords: Central serous chorioretinopathy/drug therapy; Receptors,mineralocorticoid/antagonists & inhibitors; Review
From: Chinese Journal of Ocular Fundus Diseases 2019;35(4):413-417
CountryChina
Language:Chinese
Abstract: As most patients of central serous retinopathy (CSC),the symptoms of acute onset will alleviate by oneself after 4-6 months.About 30％-50％ of patients with CSC experience chronic or recurrent cases.Resulting in persistent neurosensory detachments and subretinal fluid,causing significant vision loss.Mineralocorticoid receptor (MR) is a kind of nuclear hormone receptors,plays a role in theregulation of water and electrolyte balance.Excessive MR signaling is associated with many diseases.Study found that MR antagonists decreased the thickness of the retina and improved in vision,there was no serious adverse reactions during the period of treatment.Initial dose of MR antagonists was 25 mg per day,1 week later,dosage was increased to 50 mg per day,and treatment for about 3 months.There is no conclusive effective treatment and the dosage are still unknown.MR antagonists may be a safe and effective way to treat CSC,though evidence is scant.Prospective,multicenter,large-scale trials is required.